View Older Stories View More Recent Stories

Feb 17, 2021 08:00AM Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development
Feb 8, 2021 08:08AM Cue Biopharma Inc. (CUE) Begins Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA (pembrolizumab)
Feb 8, 2021 08:00AM Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer
Feb 8, 2021 08:00AM Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer
Nov 23, 2020 08:00AM Cue Biopharma to Present at the Piper Sandler 32nd Annual Healthcare Conference
Nov 23, 2020 08:00AM Cue Biopharma to Present at the Piper Sandler 32nd Annual Healthcare Conference
Nov 19, 2020 08:00AM Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck
Nov 19, 2020 08:00AM Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck
Nov 17, 2020 04:01PM Cue Biopharma Reports Third Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates
Nov 17, 2020 04:01PM Cue Biopharma Reports Third Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates
Nov 11, 2020 08:00AM Cue Biopharma to Present at Upcoming Investor Conferences in November 2020
Nov 11, 2020 08:00AM Cue Biopharma to Present at Upcoming Investor Conferences in November 2020
Nov 10, 2020 08:00AM Cue Biopharma to Host Business Update Call and Webcast
Nov 10, 2020 08:00AM Cue Biopharma to Host Business Update Call and Webcast
Nov 9, 2020 08:06AM Cue Biopharma Inc. (CUE) Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at
Nov 9, 2020 08:00AM Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the Societ
Nov 9, 2020 08:00AM Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the Societ
Oct 19, 2020 08:00AM Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting
Oct 19, 2020 08:00AM Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting
Sep 17, 2020 08:08AM Cue Biopharma Inc. (CUE) Names Tamar Howson to Board
Sep 17, 2020 08:00AM Cue Biopharma Welcomes Tamar Howson to its Board of Directors
Sep 17, 2020 08:00AM Cue Biopharma Welcomes Tamar Howson to its Board of Directors
Sep 15, 2020 08:10AM Cue Biopharma Inc. (CUE) Announces Nature Methods Publication of Preclinical Data Showing Tumor Penetration and Antigen-Specific T Cell Engagement with Immuno-STAT Based Protein Scaffolds
Sep 15, 2020 08:00AM Cue Biopharma Announces Nature Methods Publication of Preclinical Data Showing Tumor Penetration and Antigen-Specific T Cell Engagement with Immuno-STAT Based Protein Scaffolds
Sep 15, 2020 08:00AM Cue Biopharma Announces Nature Methods Publication of Preclinical Data Showing Tumor Penetration and Antigen-Specific T Cell Engagement with Immuno-STAT Based Protein Scaffolds
Sep 3, 2020 08:00AM Cue Biopharma to Present at Upcoming Investor Conferences in September 2020
Sep 3, 2020 08:00AM Cue Biopharma to Present at Upcoming Investor Conferences in September 2020
Aug 31, 2020 04:01PM Cue Biopharma Reports Second Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates
Aug 31, 2020 04:01PM Cue Biopharma Reports Second Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates
Aug 24, 2020 08:00AM Cue Biopharma to Present at the 16th Annual PEGS Boston Essential Protein Engineering & Cell Therapy Summit
Aug 24, 2020 08:00AM Cue Biopharma to Present at the 16th Annual PEGS Boston Essential Protein Engineering & Cell Therapy Summit
Aug 17, 2020 08:00AM Cue Biopharma to Host Business Update Call and Webcast
Aug 17, 2020 08:00AM Cue Biopharma to Host Business Update Call and Webcast
Jul 28, 2020 08:04AM Cue Biopharma Inc. (CUE) Initiates Cohort 5 Patient Dosing in Ongoing Phase 1 Monotherapy Trial of CUE-101 in HPV+ Recurrent/Metastatic Head and Neck Cancer
Jul 28, 2020 08:00AM Cue Biopharma Begins Dosing Cohort 5 in an Ongoing Phase 1 Monotherapy Trial of CUE-101 in HPV+ Recurrent/Metastatic Head and Neck Cancer
Jul 28, 2020 08:00AM Cue Biopharma Begins Dosing Cohort 5 in an Ongoing Phase 1 Monotherapy Trial of CUE-101 in HPV+ Recurrent/Metastatic Head and Neck Cancer
Jul 8, 2020 08:07AM Cue Biopharma Inc. (CUE) Reports Publication of Data Focused Primarily on B7-1 & PD-L1 Novel Molecules with Directed Mutations within B7 Superfamily
Jul 8, 2020 08:00AM Cue Biopharma Announces PLOS One Publication Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within the B7 Superfamily
Jul 8, 2020 08:00AM Cue Biopharma Announces PLOS One Publication Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within the B7 Superfamily
Jun 15, 2020 08:04AM Cue Biopharma Inc. (CUE) Provides Update on Ongoing Phase 1 Trial Evaluating CUE-101 in Recurrent/Metastatic Head and Neck Cancer
Jun 15, 2020 08:00AM Cue Biopharma Provides Update on Ongoing Phase 1 Trial Evaluating CUE-101 in Recurrent/Metastatic Head and Neck Cancer
Jun 15, 2020 08:00AM Cue Biopharma Provides Update on Ongoing Phase 1 Trial Evaluating CUE-101 in Recurrent/Metastatic Head and Neck Cancer
May 28, 2020 08:00AM Cue Biopharma to Present Corporate Overview and Pipeline Progress at Jefferies Virtual Healthcare Conference
May 28, 2020 08:00AM Cue Biopharma to Present Corporate Overview and Pipeline Progress at Jefferies Virtual Healthcare Conference
May 19, 2020 04:01PM Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights
May 19, 2020 04:01PM Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights
May 18, 2020 08:00AM Cue Biopharma to Present at AACR Virtual Annual Meeting
May 18, 2020 08:00AM Cue Biopharma to Present at AACR Virtual Annual Meeting
May 14, 2020 08:00AM Cue Biopharma Announces Strategic Research Collaboration with Dr. Michael Dustin and Oxford University
May 14, 2020 08:00AM Cue Biopharma Announces Strategic Research Collaboration with Dr. Michael Dustin and Oxford University
View More Recent Stories View Older Stories